Ocular health of patients with relapsed/refractory multiple myeloma (RRMM): Baseline data from the DREAMM-2 trial of belantamab mafodotin (Belamaf)

Authors
Category Primary study
ConferenceBlood
Year 2020
This article has no abstract
Epistemonikos ID: 80264511121d7d028013d1125256c7fb132e52d2
First added on: Feb 12, 2025